Korean J Gastroenterol.  2014 Oct;64(4):206-212. 10.4166/kjg.2014.64.4.206.

Clinical Correlation between Serum Cytokeratin-18 and Metabolic Parameters in Patients with Sonographic Non-alcoholic Fatty Liver Disease

• Kwak DS
• Jun DW
• Cho YK
• Lee SM
• Lee SH
• Jung IS
• Lee SW
• Park JK
• Lee J
• Lee EY
• Rho M
• Lee KL
• Ko JK
• Park SE

• KMID: 1979205
• DOI: http://doi.org/10.4166/kjg.2014.64.4.206

Abstract

BACKGROUND/AIMS
The serum cytokeratin-18 (CK-18) has been suggested to be a surrogate marker of non-alcoholic fatty liver disease (NAFLD). The aim of this study was to investigate the correlation between CK-18 and metabolic parameter in NAFLD patients. Correlation between CK-18 and macronutrient composition was also assessed.
METHODS
A total of 212 subjects were recruited. Blood chemistry including fasting glucose, cholesterol level, AST, ALT, and CK-18 were compared. Data on calorie intake and carbohydrate consumption were acquired by five-day-diet diary using 24 hour recall method.
RESULTS
Plasma CK-18 were markedly increased in patient with NAFLD compared with control group (420.4+/-282.3 vs. 313.6+/-179, p<0.001). Plasma CK-18 were positively correlated with systolic blood pressure (r=0.130), ALT (r=0.503) and negatively correlated with HDL cholesterol (r=-0.246). NAFLD patients with metabolic syndrome had higher CK-18 level than those without metabolic syndrome (484.0 vs. 372.1 U/L, p=0.021). When NAFLD patients were subdivided into two groups with CK-18 cut-off value of 400 U/L, patients with CK-18 level over 400 U/L showed higher body mass index (28.0+/-4.5 vs. 25.5+/-4.3), subcutaneous abdominal fat (283.5+/-172.2 vs. 195.7+/-147.8), AST (52.7+/-26.3 vs. 40.7+/-23.5) and ALT (102.0+/-52.6 vs. 61.2+/-32.2). Calorie intake (r=0.301) and carbohydrate intake (r=0.305) also showed positive correlation with CK-18.
CONCLUSIONS
Plasma CK-18 showed positive correlation with metabolic parameters as well as calorie and carbohydrate intake when its cut-off value of greater than 400 U/L was used.

Keyword

Non-alcoholic fatty liver disease; Keratin-18; Metabolic syndrome; Carbohydrates

MeSH Terms

Abdominal Fat
Biological Markers
Blood Pressure
Body Mass Index
Carbohydrates
Chemistry
Cholesterol
Cholesterol, HDL
Fasting
Fatty Liver*
Glucose
Humans
Keratin-18*
Plasma
Ultrasonography*
Biological Markers
Carbohydrates
Cholesterol
Cholesterol, HDL
Glucose
Keratin-18

Figure

• 

  Fig. 1. Serum cytokeratin-18 (CK-18) level according to disease subgroups. Serum CK-18 level of nonalcoholic fatty liver disease (NAFLD) group was higher than that of control group. Presence of metabolic syndrome (MS) further increased serum CK-18 level in patients with nonalcoholic fatty liver disease. p<0.05 by ANOVA test.

Reference

References

1. Jeong EH, Jun DW, Cho YK, et al. Regional prevalence of nonalcoholic fatty liver disease in Seoul and Gyeonggi-do, Korea. Clin Mol Hepatol. 2013; 19:266–272.

2. Park YJ, Lim JH, Kwon ER, et al. Development and validation of a simple index system to predict nonalcoholic fatty liver disease. Korean J Hepatol. 2011; 17:19–26.

3. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006; 44:865–873.

4. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006; 44:27–33.

5. Feldstein AE, Werneburg NW, Canbay A, et al. Free fatty acids pro-mote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology. 2004; 40:185–194.

6. Ramalho RM, Cortez-Pinto H, Castro RE, et al. Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis. Eur J Gastroenterol Hepatol. 2006; 18:21–29.

7. Papatheodoridis GV, Hadziyannis E, Tsochatzis E, et al. Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection. Gut. 2008; 57:500–506.

8. Abdel Haleem H, Zayed N, Abdel Hafez H, et al. Evaluation of the diagnostic value of serum and tissue apoptotic cytokeratin-18 in patients with chronic hepatitis C. Arab J Gastroenterol. 2013; 14:68–72.

9. Gonzalez-Quintela A, García J, Campos J, et al. Serum cytoker-atins in alcoholic liver disease: contrasting levels of cytoker-atin-18 and cytokeratin-19. Alcohol. 2006; 38:45–49.

10. Zeng MD, Fan JG, Lu LG, et al. Chinese National Consensus Workshop on Nonalcoholic Fatty Liver Disease. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. J Dig Dis. 2008; 9:108–112.

11. Han JM, Jo AN, Lee SM, et al. Associations between intakes of individual nutrients or whole food groups and nonalcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol. 2014; 29:1265–1272.

12. Alberti KG, Eckel RH, Grundy SM, et al. International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120:1640–1645.

13. Shim YJ, Paik HY. Reanalysis of 2007 Korean national health and nutrition examination survey (2007 KNHANES) results by CAN-Pro 3.0 nutrient database. Korean J Nutr. 2009; 42:577–595.

14. The Korean Dietetic Assocation. Guessing food amount by picture. Seoul: KDA;1999.

15. Hyun WJ, Song GH, Choi MK, Son SM. Food enegy and nutrient composition table easy to understand. Seoul: The Korean Society of Community Nutrition;2007.

16. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005; 129:113–121.

17. Kim YS, Jung ES, Hur W, et al. Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease. Clin Mol Hepatol. 2013; 19:120–130.

18. Kwok R, Tse YK, Wong GL, et al. Systematic review with meta-analysis: noninvasive assessment of nonalcoholic fatty liver disease–the role of transient elastography and plasma cy-tokeratin-18 fragments. Aliment Pharmacol Ther. 2014; 39:254–269.

19. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012; 142:1592–1609.

20. Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2013; 19:325–348.

21. Miyasato M, Murase-Mishiba Y, Bessho M, et al. The cytoker-atin-18 fragment level as a biomarker of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Clin Chim Acta. 2014; 433:184–189.

22. Cusi K, Chang Z, Harrison S, et al. Limited value of plasma cyto-keratin-18 as a biomarker for NASH and fibrosis in patients with nonalcoholic fatty liver disease. J Hepatol. 2014; 60:167–174.

23. Hession M, Rolland C, Kulkarni U, Wise A, Broom J. Systematic review of randomized controlled trials of low-carbohydrate vs. low-fat/low-calorie diets in the management of obesity and its comorbidities. Obes Rev. 2009; 10:36–50.